Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16953352 | 0.80 | LMNA (0.38) | LMNACA1CA2TSHRALDH1A1 | |
| SCHEMBL8150226 | 0.80 | LMNA (0.38) | LMNACA1CA2TSHRALDH1A1 | |
| SCHEMBL98563 | 0.79 | LMNA (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1232196 | 0.78 | LMNA (0.58) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL832 | 0.78 | TSHR (0.46) | LMNACA1CA2TSHRALDH1A1 | |
| SCHEMBL3023051 | 0.78 | MEN1 (0.42) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL9316451 | 0.76 | ALDH1A1 (0.43) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL1515849 | 0.76 | ERN1 (0.55) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL2895077 | 0.76 | MEN1 (0.41) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL5381815 | 0.76 | ERN1 (0.42) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | HINOVA PHARMACEUTICALS INC. (CN) | 2025-12-16 | — | — | US | disclosed |
| CN-112574189-B | EP300/CBP inhibitor | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117736222-A | MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures | 烨辉医药科技(上海)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023122093-A1 | REV-ERB AGONISTS FOR TH17-MEDIATED INFLAMMATORY DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230027088-A1 | EP300/CBP INHIBITOR | HINOVA PHARMACEUTICALS INC. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-4043458-A1 | EP300/CBP INHIBITOR | Hinova Pharmaceuticals Inc. (CN) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021057915-A1 | EP300/CBP INHIBITOR | 成都海创药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057915-A1 | EP300/CBP INHIBITOR | 成都海创药业有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574189-A | EP300/CBP inhibitor | 海创药业股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-109952289-A | TRPV4 antagonist | 葛兰素史密斯克莱知识产权（第2 号）有限公司 | 2019-06-28 | — | — | CN | disclosed |
| WO-2011157339-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2011-12-22 | — | — | WO | disclosed |
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| CN-1675209-A | Dihydropyrazolopyridine compounds | MITSUBISHI PHARMA CORP (JP) | 2005-09-28 | — | — | CN | disclosed |
| CN-1630656-A | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORP (JP) | 2005-06-22 | — | — | CN | disclosed |
| EP-1537106-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2005-06-08 | — | — | EP | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| WO-2004014910-A1 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-02-19 | — | — | WO | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062795-A9 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497392-B2 | EP300/CBP inhibitor | EP300, MLLT1, CREBBP | LMNA 2821/4885KMT2A 153/4885MEN1 1021/4885 |
| US-20230027088-A1 | EP300/CBP INHIBITOR | EP300, MLLT1, CREBBP | LMNA 2821/4885KMT2A 153/4885MEN1 1021/4885 |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | LMNA 3445/4885KMT2A 3396/4885MEN1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.